.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX26_MirvetuximabSoravtansine.MirvetuximabSoravtansine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX26_MirvetuximabSoravtansine.MirvetuximabSoravtansine| name: | MirvetuximabSoravtansine |
| ATC code: | L01FX26 | route: | intravenous |
| n-compartments | 2 |
Mirvetuximab soravtansine is an antibody-drug conjugate composed of a folate receptor alpha (FRα) targeting monoclonal antibody linked to the cytotoxic agent DM4 (a maytansinoid tubulin inhibitor). It is used for the treatment of adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug has received FDA approval for use in these indications.
Pharmacokinetics reported in adults with advanced solid tumors, including ovarian cancer, receiving intravenous mirvetuximab soravtansine. Parameters represent typical findings in these patient populations.
Tu, YP, et al., & Berkenblit, A (2024). Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite. British journal of clinical pharmacology 90(2) 568–581. DOI:10.1111/bcp.15937 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37872122